No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 0.1x · 10Y median 307.1x · 2nd percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T17:51:46.445Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for HCW Biologics Inc. (HCWB) stock was $1.60 as of Oct 6, 2026, 1:29 PM EDT, down 2.44% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -93.2% · 3-year avg -84.7%/yr · 5-year avg -69.7%/yr
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies.
Biotechnology · Miramar, FL
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-1.35
Revenue Est.
$118652.00
Last Quarter Results
EPS
$-11.58
vs Estimate
$-1.98
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1HCWB | $556,226 | $1.60 | -2.44% | -93.15% | -69.71% | N/A | N/A |
| 2VIVS | $522,716 | $0.20 | -1.41% | -93.85% | N/A | N/A | vs HCWB |
| 3XRTX | $483,178 | $1.74 | +2.06% | -57.33% | -63.52% | N/A | vs HCWB |
| 4CDT | $675,466 | $0.88 | -4.50% | N/A | N/A | N/A | vs HCWB |
| 5NIKI | $389,261 | $4.78 | +1.09% | -97.86% | -71.40% | N/A | vs HCWB |
| 6RDGT | $801,745 | $0.89 | +0.61% | -99.53% | -86.91% | -67.34% | vs HCWB |
forward FY estimate
N/A
$135568.00
vs Estimate
$135568.00
Consensus Rating
Based on 1 analyst
Average Price Target
$48.00
+2900.0% upside
Low
$48.00
Current
$1.60
High
$48.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-1.08 | $-1.08 | $-1.08 | 1 |
| Quarter ending Dec 2026 | $-1.08 | $-1.08 | $-1.08 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.88 | $-2.88 | $-2.88 | 1 |
| FY 2027 | $-2.64 | $-2.64 | $-2.64 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $118652.00 | $118652.00 | $118652.00 | 1 |
| Quarter ending Dec 2026 | $103847.00 | $103847.00 | $103847.00 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $6.54M | $6.54M | $6.54M | 1 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| FY 2027 |
| $33.73M |
| $33.73M |
| $33.73M |
| 1 |
